Evaluation of bioequivalence and safety analysis of capecitabine tablets and Xeloda® under postprandial dosing conditions in Chinese patients with solid tumor-Reference-Cited by-同舟云学术

Evaluation of bioequivalence and safety analysis of capecitabine tablets and Xeloda® under postprandial dosing conditions in Chinese patients with solid tumor

Published:2023-12-02 Issue:12 Volume:19 Page:1015-1021
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Li Hongtao¹²,Shan Rongfang¹³,Ding Jiaxiang¹⁴,Zhang Jialin¹,Liu Bingyan¹,Ge Qin¹,Cheng Dongmei¹,Li Lufeng¹,Zhang Chaoyang¹,Su He¹,Li Xiaoyue¹,Li Huiru¹,Ye Jingjing¹,Li Hui²,Li Fengxian²,Zhou Huan¹³⁴,Huo Qiang³,Su Yue¹

Affiliation:

1. National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

2. Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

3. School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China

4. School of Public Basic, Bengbu Medical College, Bengbu, Anhui, China

Funder

the Natural science research projects focus on projects in colleges and universities in Anhui Province

Anhui Biochemical Engineering Centre Research Platform Project

512 Talent Cultivation Program of Bengbu Medical College

Young Scientist Fund of Bengbu Medical College

Jiangsu Chengkang Pharmaceutical Co

Publisher